[Maxigen Biotech] May 2026 Revenue Reaches NT$73.6 Million (Down 4.4% YoY)
Maxigen Biotech Inc. (code: 1783), a biotechnology and medical care company, announced its May 2026 revenue of NT$73,604 thousand (approx. NT$74 million), representing a 4.4% decrease compared to the same period last year.
📋 Article Processing Timeline
- 📰 Published: May 1, 2026 at 09:00
- 🔍 Collected: June 12, 2026 at 08:00 (1007h 0m after Published)
- 🤖 AI Analyzed: June 12, 2026 at 16:42 (8h 41m after Collected)
Company Code: 1783
Company Name: Maxigen Biotech Inc.
Industry: Biotechnology and Medical Care
Data Month/Year: May 2026
Monthly Revenue: NT$73,604 thousand (approx. NT$74 million)
YoY Change: -4.4%
This monthly revenue report highlights the financial performance of Maxigen Biotech Inc. for May 2026, showing a slight year-over-year decline.
Company Name: Maxigen Biotech Inc.
Industry: Biotechnology and Medical Care
Data Month/Year: May 2026
Monthly Revenue: NT$73,604 thousand (approx. NT$74 million)
YoY Change: -4.4%
This monthly revenue report highlights the financial performance of Maxigen Biotech Inc. for May 2026, showing a slight year-over-year decline.
FAQ
What is Maxigen Biotech's revenue for May 2026?
The revenue for May 2026 is NT$73,604 thousand (approx. NT$74 million), representing a YoY decline of 4.4%.
What industry does Maxigen Biotech operate in?
Maxigen Biotech operates within the 'Biotechnology and Medical Care' sector.
What is the strategic takeaway from the May 2026 revenue?
While revenue decreased slightly by 4.4% YoY, it reflects minor monthly fluctuations rather than a major shift in fundamentals.